Summary [1311]meta-iodobenzylguanidine ([1311]MIBG) provides a means of selectively delivering radiation to neuroblastoma cells and is a promising addition to the range of agents used to treat neuroblastoma. As MIBG is now being incorporated into multimodal approaches to therapy, important questions arise about the appropriate scheduling and sequencing of the various agents employed. As the ability of neuroblastoma cells to actively accumulate MIBG is crucial to the success of this therapy, the effect of chemotherapeutic agents on this uptake capacity needs to be investigated. We report here our initial findings on the effect of cisplatin pretreatment on the neuroblastoma cell line SK-N-BE (2c). After treating these cells with therapeutically relevant concentrations of cisplatin (2 giM 
radiopharmaceutical alone is unlikely to be curative for the majority of neuroblastoma patients with advanced-stage disease. Therefore, in many treatment centres, MIBG is now often used in combination with more conventional therapies Gaze et al, 1995; Mastrangelo et al, 1995; Voute et al, 1995) . In the UK, a multicentre study of ['311 ]MIBG as primary agent followed by multiagent chemotherapy has recently commenced (Gaze and Wheldon 1996) . Accordingly, it is important to establish the optimal scheduling of different treatment modalities. On theoretical grounds, maximal benefit should be obtained when [131I] MIBG administration precedes combination chemotherapy (Gaze and Wheldon, 1996) . This is because chemotherapy-induced tumour regression could lead to reduced MIBG uptake in dead or dying cells resulting in less killing of surviving cells by radiation cross-fire. However, the effect of prior exposure of tumour cells to cytotoxic drugs upon MIBG accumulation has yet to be defined.
Nonetheless, it is known that the administration of therapeutic agents can modulate the ability of cultured neuroblastoma cells to transport MIBG. For example, Smets et al (1991) have shown that 5 Gy external beam irradiation stimulated MIBG uptake by neuroblastoma cells in vitro. The effect may have been due to the selective depletion of proliferating cells, suggesting that the more differentiated component of the culture had greater capacity for the active uptake of MIBG. This hypothesis was supported by the observation of a twofold enhancement of the uptake of MIBG by neuroblastoma cells after 3 days exposure to interferon-gamma which induced morphological changes indicative of a more mature phenotype (Montaldo et al, 1992) . This was accompanied by increased transcription of the noradrenaline transporter gene, suggesting that differentiation-inducing agents, which up-regulate the expression of neuronal-specific genes, could be used in conjunction with MIBG in neuroblastoma patients to enhance the uptake by tumours of the radiopharmaceutical.
The efficacy of cisplatin administration in combination with ['311 ]MIBG is undergoing clinical evaluation (Mastrangelo et al, 1995) . Therefore, we have studied the influence of cisplatin preincubation on the uptake and retention of MIBG and on the expression of the noradrenaline transporter gene by neuroblastoma cells.
MATERIALS AND METHODS Cell lines
The human neuroblastoma cell line SK-N-BE (2c) was used for these studies. This cell line was derived from the bone marrow of a patient with progressive neuroblastoma following treatment with radiotherapy and chemotherapy (Beidler et al, 1978) , and it has a high capacity for uptake of MIBG (Mairs et al, 1994) .
Culture conditions
Cells were grown in a 5% carbon dioxide atmosphere at 37°C in RPMI-1640 medium supplemented with 10% fetal calf serum, penicillin/streptomycin (100 IU ml-'), amphotericin B (2 mg ml-') and glutamine (200 mM). All media and supplements were obtained from Gibco (Paisley, UK). Effect of culture density on MIBG uptake and noradrenaline transporter gene expression
The influence of cell culture density on the active incorporation of MIBG was determined using SK-N-BE(2c) cells that had not been subjected to treatment with cisplatin. Transcription by SK-N-BE(2c) cells of the noradrenaline transporter gene was assessed by reverse transcription-polymerase chain reaction (RT-PCR). Cells
MIBG release experiments
To determine whether cisplatin treatment affected storage capacity of the neuroblastoma cells, experiments were carried out to investigate the kinetics of release of MIBG from control and treated cells. At 48 h after initial cisplatin exposure, cells were incubated with labelled MIBG as described above. The culture medium was then removed and changed for drug-free fresh medium or medium containing 1.5 ,UM DMI. In a second set of cultures, medium was replaced with drug-free fresh medium or medium containing 2 gM reserpine. At 0, 2, 4 and 6 h after withdrawal of MIBG, the cells were assayed for MIBG retention. Data were analysed using the Student's t-test.
RT-PCR analysis of noradrenaline transporter gene expression were determined by A260 measurements. One microgram of RNA was reverse transcribed using random hexamer primers, and the resultant cDNA was PCR amplified using primers specific for the transporter sequence. The sense primer was 5'-CTGGTGGTGAAG-GAGCGCAACGGC-3', and the antisense primer was 5'-ATGT-CATGAATCCCGCTGCTCTCG-3' (Montaldo et al, 1992) . This amplification generated a 590-bp PCR product. Semiquantitation was achieved by comparison of the target signal with the signal generated by co-amplification of a reference sequence glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The GAPDH primers were 5'-GCATTGCTGATGATCTTGAGGC-3' (sense) and 5'-TCGGAGTCAACGGATT'GG-3' (antisense). These generated a 300-bp PCR product. Co-amplification of target and reference sequences was performed in 10 x synthesis buffer containing 100 mM Tris-HCl, 15 mm magnesium chloride, 500 mm potassium chloride, pH 8.3 with 10 nmol of dNTPs, 20 pmol of each target primer, 20 pmol of each reference GAPDH primer and 2 units of Taq polymerase. Cycling conditions consisted of 1 min denaturation at 94°C, 1 min annealing at 65°C and 1 min extension at 72°C for 35 cycles. The PCR products were separated by electrophoresis through 1.6% (w/v) agarose (Flowgen, Kent, UK). These were densitometrically scanned using Quality One Image Analysis software.
RESULTS

Effect of culture density
Initial experiments were undertaken to monitor the effects of culture density on MIBG uptake and transporter expression. These confirmed the previous observations (Montaldo et al, 1992 ) that at high culture densities (greater than 0.24 x 105 cells cm-2 which is equivalent to 2.5 x 105 cells per well) there was a progressive decline in MIBG accumulation (Figure 1 ). RT-PCR analysis confirmed that this reduction in uptake was due to decreased expression of the gene encoding the noradrenaline transporter (Table 1) . Accordingly, in all cisplatin experiments, cell numbers in control and treated cultures were kept below this figure. Data from wells containing more than 2.5 x 105 cells were discarded. Effect of cisplatin on SK-N-BE(2c) survival The toxicity of a range of concentrations of cisplatin was determined by clonogenic assay. Figure 2 shows that the toxic effects of cisplatin were apparent at concentrations of the drug greater than 0.2 gM.
British Journal of Cancer (1997) Table 2 . These data demonstrate that cisplatin induced a dose-dependent stimulation of expression of the transporter molecule. At 0.02 gM and 0.2 gm levels of cisplatin, the enhanced expression was not maintained after removal of the drug.
However at higher concentrations (2.0 and 20 gM), the effect was prolonged and was in fact greater at 48 h than at 24h after the initiation of exposure to cisplatin. These results indicate that the cisplatin-induced enhancement of MIBG uptake was due to increased synthesis of new transporter molecules -as opposed to increased activity of existing molecules.
Effect of cisplatin pretreatment on retention of MIBG
To determine whether cisplatin enhanced the ability of SK-N-BE(2c) cells to store catecholamines, experiments were carried out to determine the retention of MIBG. These were performed in the presence of reserpine (which depletes neurosecretory granules) and DMI (which inhibits re-uptake of released drug by the transporter). In control-and cisplatin-treated cells, spontaneous release Sterilisation of cells surviving earlier treatment of MIBG was similar to that in the presence of reserpine. In contrast, DMI induced a rapid depletion of MIBG from the cells ( Figure 5 ). These results show that the cisplatin-treated cells maintain levels of MIBG by continual re-uptake of released drug via the noradrenaline transporter. Cisplatin did not induce the cells to develop reserpine-sensitive storage granules as no statistically significant difference in the retention of radiopharmaceutical was observed in the presence or abscence of reserpine (P>0. 1).
DISCUSSION
It may be possible to improve MIBG-targeted radiotherapy for neuroblastoma by increasing the capacity of tumour cells for active uptake or retention of the radiopharmaceutical. Because of the growing interest in combining MIBG-targeted radiotherapy with other treatment modalities (Gaze and Wheldon, 1996) , it is important to establish the optimal sequence of administration of treatments. The present study focused on the effect of cisplatin pretreatment upon the accumulation and retention of MIBG by neuroblastoma cells. Cisplatin was selected for study because it is used effectively in the treatment of neuroblastoma (Pinkerton et al, 1990; De Bernardi et al, 1992; Pearson et al, 1992) and because it may act in synergy with radiotherapy (Dewit, 1987) . Our results clearly demonstrate that neuroblastoma cells preincubated with therapeutically relevant doses of cisplatin, which induced approximately one log cell kill in vitro, more efficiently concentrated MIBG than untreated controls. The enhanced accumulation of radiopharmaceutical does not appear to be a result of elevated proficiency of granular storage as the MIBG content of the cells was unaffected by treatment with 2 gM reserpine.
Conversely, desmethylimipramine, a tricyclic antidepressant which is a specific inhibitor of the active uptake of neurotransmitters by adrenergic neurones, caused the depletion of MIBG from cisplatintreated cells. This suggests that the cisplatin-enhanced MIBG uptake resulted from an increased capacity to actively accumulate the drug. This notion is supported by the observation of a cisplatinprovoked (dose-dependent) stimulation of the transcription of the noradrenaline transporter gene. The latter outcome may be a reflection of the more highly differentiated cellular phenotype which is inducible by cisplatin (Doi et al, 1995; Kumar and Singh, 1995) or cisplatin analogues (Maurer et al, 1993) .
The mode of cell death induced by cisplatin is complex, dosedependent and influenced by cellular phenotype. At supralethal concentrations of cisplatin (100 gM), rapid apoptotic death occurred in a murine leukaemic cell line, whereas lower concentrations (1-10 tM) caused G2 arrest followed by slow non-apoptotic death (Ormerod et al, 1994) . Others have shown that, in human lymphoblastoid cells, DNA damage by cisplatin may result in p53-mediated apoptosis of cells in G,/S-phase or p53-independent apoptosis of p53 mutant cells in G2/M-phase of the cell cycle (Allday et al, 1995) . It has been demonstrated previously that SK-N-BE(2c) cells respond to cisplatin treatment by undergoing G,/M blockade and subsequent apoptosis (Piacentini et al, 1993) .
Treatments which enhance uptake of MIBG by neuroblastoma cells in culture include ionizing radiation, interferon-y and phorbol esters (Smets et al, 1991; Montaldo et al, 1992 Montaldo et al, , 1996 . In common with these agents, cisplatin causes perturbations of the DNA which in turn up-regulate p53 expression. Cisplatin can induce the expression of p53-dependent genes, such as the CIPI gene, encoding the cell cycle kinase inhibitor p21 (El -Deiry et al, 1994) . It is possible that cisplatin enhancement of the cellular accumulation of MIBG results from transcriptional transactivation of the noradrenaline transporter gene via a putative p53 consensus sequence in the promoter.
In addition to the activation of apoptosis by the formation of DNA adducts (Cece et al, 1995; Dole et al, 1995) cisplatin may inhibit the growth of neuroblastoma cells by virtue of its capacity to promote differentiation. Indeed, a range of cytotoxic agents, including epirubicin and tiazofurin (Rocchi et al, 1987; Pillwein et al, 1993) , and gamma irradiation (Rocchi et al, 1993) have been shown to induce biochemical as well as morphological evidence of differentiation of neuroblastoma in vitro. Cisplatin has been reported to induce neurite outgrowth at concentrations of 0.4-13.2 gM (Konings et al, 1994) . These doses are within the range of plasma concentrations achieved during therapy (Ardiet et al, 1989) .
In the population of cells which survived cisplatin treatment, the relative proportions of cycling cells, quiescent cells, clonogens and doomed cells are not known. Therefore, the cellular phenotype (subpopulation) which displayed an increased capacity for active uptake of MIBG cannot be assigned with certainty. However, a previous study involving six neuroblastoma cell lines revealed a strong linear correlation between capacity for active uptake of MIBG and expression of the noradrenaline transporter gene (Mairs et al, 1994) . This suggests that the latter phenomenon may be partly or wholly responsible for the increased accumulation of radiopharmaceutical by cisplatin-treated cells and that this characteristic is probably a manifestation of more mature neuroblasts, as previously demonstrated in neuroblastoma cultures exposed to maturation-inducing agents (Montaldo et al, 1992) .
From a therapeutic perspective, the most important consideration in the use of I3'l-labelled radiopharmaceuticals is maximization of beta-particle cross-fire irradiation from targeted regions of tumour to adjacent malignant cells. In a treatment regimen involving the delivery of cisplatin followed by ['31I ]MIBG, it is probable that even those cells which are destined to die as a result of cisplatin administration could contribute to the radiation crossfire effect by virtue of their increased uptake of the radiopharmaceutical. Therefore, regardless of the cellular sub-type responsible for the increase in MIBG accumulation, the therapeutic outcome of the enhanced expression of the noradrenaline transporter would be an increase in beta-decay particle energy deposition within tumour sites. Recently, cisplatin has been used in combination with ['311 ]MIBG for the therapy of relapsed neuroblastoma patients with progressive disease (Mastrangelo et al, 1995) . In this unpromising group, a very impressive response rate of 67% was obtained. Interestingly, the therapeutic regimen involved two injections of cisplatin, administered one week apart, both followed one day later by injection of ['3'I] It is important to note that the increased accumulation of MIBG after chemotherapy, reported in this paper, has been seen to occur for up to 48 h following treatment; but studies of longer-term effect, most appropriately using in vivo models, have not yet been undertaken. Theoretical arguments favouring [113]MIBG as primary treatment followed by intensive chemotherapy regimens (Gaze and Wheldon, 1996) remain in place and are not obviated by these findings over a 2-day period. It is not theoretically optimal that initial chemotherapy should be of such intensity and duration as to cause extensive cell kill and tumour regression before ['31I]MIBG treatment is given. However, the present studies do raise the possibility that initial brief exposure to cisplatin, perhaps a single treatment, at first presentation could then be followed by ['311I ]MIBG and a more intensive combination to achieve maximum therapeutic benefit (see Figure 6 ).
CONCLUSION
This study indicates that a potentially important consequence of the treatment of neuroblastoma cells with cisplatin is the improved capacity for active accumulation of MIBG. Exploitation of this effect by appropriate scheduling of cisplatin and ['311]MIBG administration could facilitate augmented tumour cell kill because of maximization of radiation cross-fire from 'r'I disintegration.
